Host: Darryl S. Chutka, M.D. [@chutkaMD]

Guest: Daniel M. Frendl, M.D., Ph.D.

Prostate cancer is one of the most common malignancies in men, second only to skin cancer. It’s estimated that 1 in 8 men will develop prostate cancer during their lifetime. The predominant screening test for prostate cancer has been the prostate specific antigen or PSA.  However, there has been some controversy surrounding the use of PSA. It’s an easily administered test, it’s relatively inexpensive and it’s capable of identifying men with possible prostate cancer. So, what’s the controversy? Is the PSA an effective screening test? Who should be tested and how have urologists modified their practice to manage patients with an elevated PSA? We’ll discuss these questions in today’s podcast on “Screening for Prostate Cancer” with our guest, Daniel M. Frendl, M.D., Ph.D., a urologist at the Mayo Clinic.

This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.